Table 2.
Top HP, GO, and KEGG Pathway Analysis Terms Enriched in the Differentially Expressed Genes in Zebrafish Developmentally Exposed to 4 μM THC or 0.5 μM CBD
| 4 μM THC |
0.5 μM CBD |
||||
|---|---|---|---|---|---|
| No. DEG | p-Value | No. DEG | p-value | ||
| GO ID | GO Pathway | ||||
| GO:0016491 | Oxidoreductase activity | 91 | 9.29E−21 | 67 | 1.76E−05 |
| GO:0046906 | Tetrapyrrole binding | 28 | 5.39E−09 | 28 | 2.19E−07 |
| GO:0061134 | Peptidase activity | 60 | 7.15E−08 | 58 | 1.71E−04 |
| GO:0016787 | Hydrolase activity | 140 | 3.86E−05 | N/A | |
| GO:0016936 | Galactoside binding | 5 | 5.07E−04 | N/A | |
| GO:0004497 | Monooxygenase activity | N/A | 27 | 4.16E−08 | |
| HP ID | HP pathway | ||||
| HP:0004431 | Complement deficiency | 11 | 1.48E−05 | 13 | 5.19E−07 |
| HP:0001937 | Microangiopathic hemolytic anemia | 7 | 1.92E−03 | 8 | 3.86E−04 |
| HP:0011036 | Abnormality of renal excretion | N/A | 14 | 5.88E−03 | |
| HP:0005575 | Hemolytic-uremic syndrome | 7 | 1.92E−03 | 7 | 7.03E−03 |
| HP:0001919 | Acute kidney injury | N/A | 9 | 1.55E−02 | |
| KEGG ID | KEGG pathway | ||||
| KEGG:00980 | Metabolism of xenobiotics by CYP450 | 19 | 6.34E−12 | N/A | |
| KEGG:00983 | Drug metabolism—other enzymes | 21 | 7.97E−11 | N/A | |
| KEGG:00830 | Retinol metabolism | 18 | 1.44E−09 | 10 | 3.74E−02 |
| KEGG:01100 | Metabolic pathways | 106 | 3.36E−09 | 95 | 2.59E−02 |
| KEGG:00140 | Steroid hormone biosynthesis | 16 | 1.18E−08 | 10 | 1.09E−02 |
| KEGG:03320 | PPAR signaling pathway | 13 | 2.62E−03 | 13 | 1.23E−02 |
Each treatment consisted of 3 biological replicates with 10 embryos per replicate. No. DEG. = N/A.